Przegląd Gastroenterologiczny

Abstract

2/2023 vol. 18
Review paper

Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review

Ewelina Jakielska 1
,
Paweł Głuszak 1
,
Marta Walczak 2
,
Wiesław Bryl 2
  1. Student Internal Medicine Research Society, Poznan University of Medical Sciences, Poznan, Poland
  2. Department of Internal Medicine, Metabolic Disorders and Hypertension, Poznan University of Medical Sciences, Poznan, Poland
Gastroenterology Rev 2023; 18 (2): 148–153
DOI: https://doi.org/10.5114/pg.2023.126054
Online publish date: 2023/03/23
View full text
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
Metabolic-associated fatty liver disease (MAFLD), previously known as non-alcoholic fatty liver disease, is a significant epidemiological problem and a well-known cardiovascular risk factor. The increasing number of cases creates the need for new therapeutic methods aimed at improving patient outcomes. Recent studies have highlighted the relationship between MAFLD and proprotein convertase subtilisin/kexin type 9 (PCSK9). Based on the available data, PCSK9 inhibitors appear to have beneficial effects in patients with MAFLD, and they may be a treatment option in the future. Further research is necessary to better evaluate the efficiency of PCSK9 inhibitors in MAFLD treatment.

Keywords

non-alcoholic fatty liver disease, fatty liver, PCSK9

Share
without publication fees
Coverage in
Indexed in
pubmed
Integrated with
integrated with publons
plagiat pl
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications